Leadership | Perosphere Technologies Inc.

Leadership

Sasha H. Bakhru, PhD, President, Chief Executive Officer
Dr. Bakhru is a Founder of Perosphere Inc. (now Perosphere Technologies Inc. and Perosphere Pharmaceuticals Inc.), an Adjunct Assistant Professor of Medical Science at Brown University and Lecturer in Entrepreneurship. He is a member of the Scientific Advisory Board of Amylyx Pharmaceuticals. Dr. Bakhru has co-authored over 30 publications, ten patents and one book chapter; his work has been published in 40 conference proceedings and abstracts. Dr. Bakhru received a BS in Biomedical Engineering from Columbia University, an MSE from Johns Hopkins University in Materials Engineering and a PhD from Carnegie Mellon University in Biomedical Engineering as a Dowd Fellow in the Institute for Complex Engineered Systems. He was winner of the 2008 Global MOOT Corp competition, and in 2009, received the Carnegie Mellon Tepper School of Business “Entrepreneur of the Year” and “Manufacturing Entrepreneur of the Year” alumni prizes.
Alan Curtis, RAC, Vice President, Regulatory Affairs
Mr. Curtis has over 30 years experience in the medical device industry, specifically in Regulatory Affairs, Quality Systems, and Clinical Affairs. He has has provided regulatory strategies and submissions for multiple medical device disciplines and projects and has designed clinical studies to support many of these submissions. Internationally, Mr. Curtis has created Technical Files to support the CE Mark, prepared successful submissions to Health Canada, and several Pacific Rim countries. Mr. Curtis has held a variety of senior management positions including Director and Vice President in the Regulatory Affairs, Clinical, and Quality Systems areas of responsibility at companies including W.L. Gore and Associates, Viveve Medical, Aragon Surgical, and Reliant Technologies. He received a B.Sc in Microbiology and Regulatory Affairs Certification (RAC).
Xuan Jiang, PhD, Vice President, Research
Dr. Xuan Jiang joined Perosphere Inc. in 2012 and served as VP, Pre-Clinical Development supporting ciraparantag, a novel anticoagulant reversal agent, at Perosphere Pharmaceuticals Inc. from 2014 until 2018. Dr. Jiang received his BS in Polymer Science and Engineering from Fudan University in 2001, MSE in Chemistry from National University of Singapore and PhD degree in Materials Science and Engineering in 2010 from Johns Hopkins University. Dr. Jiang completed postdoctoral training at the Institute for NanoBioTechnology at Johns Hopkins in 2012. Dr. Jiang has co-authored 24 journal publications, 12 conference presentations, one book chapter and 2 US patents. Dr. Jiang has served as reviewer for several scientific journals including Biomaterials, Pharmaceutical Research, Biomacromolecules and International Journal of Nanomedicine.
Raymond R. Mandra, JD, Patent Counsel
Mr. Mandra is a former partner of the intellectual property law firm of Fitzpatrick, Cella, Harper & Scinto, where he practiced for 28 years out of their New York office. He was also chair of the firm’s biotechnology group for more than a decade. Representative clients of Mr. Mandra, while in private practice, included Allergan PLC, Astellas Pharma Inc., Bristol-Myers Squibb, Genzyme, Leo Pharma Inc., Mars Incorporated, Novartis, Pfizer, Sanofi and Warner Chilcott. Prior to entering the private practice of law, Mr. Mandra worked for nine years as a chemist for the General Foods Corporation. Mr. Mandra received his J.D., magna cum laude in 1990 from Pace University School of Law, where he was the Research and Writing Editor on the Pace Law Review. He also has an M.S. in Chemistry from Long Island University and a B.S. in Chemistry from the State University of New York at Oswego.
Solomon Steiner, PhD, Chairman of the Board
Dr. Steiner founded and served as CEO to three publicly-traded drug-delivery companies: Biodel Inc., MannKind Corp., and Emisphere Technologies, Inc. Dr. Steiner served as Biodel’s Chairman, President and Chief Executive Officer from its inception in December 2003 through March of 2010. In 1991, Dr. Steiner founded Pharmaceutical Discovery Corporation ("PDC"), a biopharmaceutical corporation and is an inventor of its Technosphere™ Technology and MedTone™ Inhaler. Dr. Steiner served as PDC’s Chief Executive Officer and Chairman of the board of directors from its inception until December 2001, when PDC was merged with two other companies to form MannKind Corporation. In 1985, Dr. Steiner founded and was Chairman of the board and President of Clinical Technologies Associates, Inc. ("CTAI"), now known as Emisphere Technologies, Inc. Under his leadership CTAI went public in February of 1989. Dr. Steiner was elected a Fellow of the American Psychological Association in 1973 for his work in psychopharmacology and has authored or co authored over 200 scientific publications. Dr. Steiner received a BA from New York University with a major in psychology and chemistry and a PhD from New York University.
Stefan Zappe, PhD, Executive Vice President and Chief Technology Officer
Dr. Zappe received his Dr.-Ing. (PhD) degree in Electrical Engineering in 2002 from Technical University of Berlin, Germany, under Prof. Ernst Obermeier. He worked as postdoctoral researcher at Stanford University and served as Assistant Professor of Biomedical Engineering at Carnegie Mellon University before he joined Perosphere Inc. in 2014. Dr. Zappe is the recipient of an NSF CAREER award, has co-authored 29 journal publications, over 60 conference presentations, one book and two book chapters. Dr. Zappe has served as reviewer for several scientific journals as well as the US National Science Foundation, the European Research Council and the Natural Sciences and Engineering Research Council of Canada.